Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

San Diego based Abide Therapeutics is collaborating with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, a validated but under-explored class of drug targets.

Under the three-­year agreement, Abide and Oxford will explore the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain.

The collaboration will combine the unique experience and capabilities of the Oxford Centre for Functional MRI of the Brain (FMRIB), led by Irene Tracey, with Abide’s unique chemoproteomics platform. The goals of the collaboration are to explore MGLL in a number of clinical indications including pain and inflammatory conditions. 

This collaboration is part of our commitment to translate research discoveries into the clinic to develop new medicines to improve survival and quality of life for patients around the world.
- Sir John Bell, Regius Professor of Medicine, University of Oxford

“This collaborative agreement is a true delight as it extends the founding vision of Abide which is to partner with enlightened academic investigators that have unique insights into how best to test novel therapies at the earliest stages of clinical development,” said Alan Ezekowitz, President and CEO of Abide.

Under the agreement, Abide will provide support for at least three Phase 1B studies as well as for directed new target discovery efforts. The collaboration has been supported through the NIHR Oxford Biomedical Research Centre

Similar stories

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'